PURPOSE: To evaluate survival rates and prognostic factors related to treatment outcomes after bladder preserving therapy including transurethral resection of @entity150 , radiotherapy (RT) with or without concurrent chemotherapy in @entity150 with a curative intent. MATERIALS AND METHODS: We retrospectively studied 50 @entity150 @entity1 treated with bladder-preserving therapy at Keimyung University Dongsan Medical Center from January 1999 to December 2010. Age ranged from 46 to 89 years (median, 71.5 years). @entity150 was the American Joint Committee on Cancer (AJCC) stage II, III, and IV in 9, 27, and 14 @entity1 , respectively. Thirty @entity1 were treated with concurrent chemoradiotherapy (CCRT) and 20 @entity1 with RT alone. Nine @entity1 received chemotherapy prior to CCRT or RT alone. Radiation was delivered with a four-field box technique (median, 63 Gy; range, 48.6 to 70.2 Gy). The follow-up periods ranged from 2 to 169 months (median, 34 months). RESULTS: Thirty @entity1 (60%) showed complete response and 13 (26%) a partial response. All @entity1 could have their own bladder preserved. Five-year @entity1349 ( @entity1349 ) rate was 37.2%, and the 5-year disease-free survival (DFS) rate was 30.2%. In multivariate analysis, @entity5 grade and CCRT were statistically significant in @entity1349 . CONCLUSION: @entity5 grade was a significant prognostic factor related to @entity1349 . CCRT is also considered to improve survival outcomes. Further multi-institutional studies are needed to elucidate the impact of RT in @entity150 .

Concurrent chemoradiotherapy improves survival outcome in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity150 :: ('MESH:D001749', 'Disease') :: ['Bladder cancer', 'bladder tumor', 'bladder cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity150 :: (MESH:D001749,Disease) :: ['muscle-invasive bladder cancer']
